Calgary, Alberta--(Newsfile Corp. - October 3, 2024) - Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF), a leader in portable NMR machines and MRI technology for industrial and research applications, is pleased to announce its participation at the upcoming Cantech Letter Investment Conference on Wednesday, October 9, 2024 in Toronto Ontario. Sean Krakiwsky, Chief Executive Officer of Nanalysis Scientific Corp. will be doing an investor presentation and participating in 1-on-1 meetings with investors at the conference.
2024 Cantech Letter Conference
Date: Wednesday, October 9, 2024
Location: Arcadian Loft, 8th floor, 401 Bay Street, Toronto, ON
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. to register
More info: https://www.cantechletter.com/conference/
Sean Krakiwsky , Chief Executive Officer of Nanalysis Scientific Corp. commented, “We are delighted to be participating in the Cantech Letter Conference as it’s an excellent platform to strengthen our connections within the capital markets. We hope to enhance our visibility, showcase our achievements, and increase our profile among the investor communities.”
About Cantech Letter Conference
The Cantech Letter Conference, recognized as Canada’s foremost technology investment event, provides up and coming technology companies with the unique opportunity to showcase their innovations and growth strategies, and participate in individual 1-on-1 meetings with potential investors and capital markets professionals. The conference serves as a hub for networking, knowledge exchange, and investment opportunities, while also featuring panel discussions with industry experts to offer insights into current trends, challenges, and opportunities within the technology sector.
About Nanalysis Scientific Corp.
About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FSE: 1N1)Nanalysis Scientific Corp. in operates two primary business segments: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms
For additional Information, please contact:
Matthew Selinger, Investor Relations
4155728152
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$0.37 |
Daily Change: | 0.02 5.71 |
Daily Volume: | 41,658 |
Market Cap: | C$41.830M |
October 22, 2024 August 28, 2024 April 04, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB